As South Africa marks 50 years since the June 1976 youth uprising for a dream of freedom, a new generation of young people dreaming of an HIV-free future gave their time, trust, and participation to help deliver a breakthrough new HIV prevention product that was launched this June, writes Ntando Yola.
If South Africa is serious about ending TB, protecting people living with HIV, and safeguarding the next generation from nicotine addiction, Parliament must finally pass the Tobacco Products and Electronic Delivery Systems Control Bill, argues Professor Lekan Ayo-Yusuf, as we mark World No Tobacco Day on May 31.
Fake and substandard medicines, along with bogus healthcare practitioners, pose a growing threat to patient safety in South Africa.
Substance abuse is both a symptom and a consequence of untreated mental illness, and government needs to urgently step in to confront this dangerous overlap, argues Gauta Mashego of SECTION27.
From 5–7 May, the Constitutional Court will hear two of the multiple challenges to the NHI Act. Sasha Stevenson, Executive Director of SECTION27, considers what will be on the line in these first potentially landmark cases that deal with the process that led to the Act.
It has been a bruising year or so for medical researchers in South Africa with the US pausing, cancelling, and then resuming some grants. But as bad as things were, what played out wasn’t the worst case scenario, and momentum is now building toward recovery.
When push comes to shove, President Cyril Ramaphosa’s talk of building a more capable state hasn’t always been backed up by the appointment of committed and capable people to key government positions. His decision regarding a new Director-General for health will say a lot about how serious he actually is about addressing the country’s many health challenges, argues Spotlight editor Marcus Low.
Healthcare funding is always about trade-offs, writes Thoneshan Naidoo, CEO of the Health Funders Association. The hardest question in healthcare is not what we would like to provide, he argues, but what we can provide sustainably, fairly and at scale.
The wins are there but the underlying reality remains, writes Professor Kogie Naidoo as she likens TB to a bridesmaid awaiting its turn to garner attention. The analogy is relevant given the overwhelming number of new TB infections and deaths each year globally for a disease persistently sitting in the shadow of other communicable and non-communicable diseases.
New TB tests have massive potential for South Africa’s struggle to get to grips with the age-old disease. Making the most of these new tests will require both ambition and smart implementation, argue Gaurang Tanna and Dr Yogan Pillay.
The persistence of TB is a reminder that medical solutions alone are not enough. Renier Coetzee and Ingrid Schoeman write that the disease thrives in conditions shaped by social injustice, including poverty, overcrowded housing, under-resourced health systems, and unequal access to care.
The only tuberculosis vaccine we have is a century old and offers only limited efficacy in children. With leading South African researchers involved in the pivotal clinical trials of three new tuberculosis vaccine candidates, we are on the verge of a major breakthrough, writes Associate Professor Angelique Kany Kany Luabeya.